These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21780343)

  • 1. Oxybutynin dependence: a case presentation.
    Mutlu EA
    Turk Psikiyatri Derg; 2011; 22(2):131-2. PubMed ID: 21780343
    [No Abstract]   [Full Text] [Related]  

  • 2. The physical dependence liabilities of oxybutynin and morphine in rats.
    Algate DR; Beard DJ
    Arzneimittelforschung; 1985; 35(10):1577-9. PubMed ID: 4074417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hallucinations after hypospadias repair.
    Swana HS; Youmans SL; Kogan BA; Bogetz MS
    J Pediatr Surg; 2006 Mar; 41(3):e33-5. PubMed ID: 16516613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
    Reiz JL; Salem P; Darke AC
    J Clin Pharmacol; 2007 Mar; 47(3):351-7. PubMed ID: 17322147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oxybutynin-Kentera].
    Duh D; Vandevijver A
    J Pharm Belg; 2007; 62(3):99-100. PubMed ID: 17955962
    [No Abstract]   [Full Text] [Related]  

  • 6. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial.
    Leung DY; Kwong YY; Lam DS
    Br J Clin Pharmacol; 2005 Dec; 60(6):668; author reply 669. PubMed ID: 16305595
    [No Abstract]   [Full Text] [Related]  

  • 7. Psychotic disorder induced by oxybutynin: Presentation of two cases.
    Gulsun M; Pinar M; Sabanci U
    Clin Drug Investig; 2006; 26(10):603-6. PubMed ID: 17163294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuropsychiatric adverse effects attributed to use of oxybutynin].
    t'Veld BA; Kwee-Zuiderwijk WJ; van Puijenbroek EP; Stricker BH
    Ned Tijdschr Geneeskd; 1998 Mar; 142(11):590-2. PubMed ID: 9623118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of oxybutynin dependency.
    Guloksuz S; Eren K; Gurol DT
    Gen Hosp Psychiatry; 2010; 32(4):e5-6. PubMed ID: 20633735
    [No Abstract]   [Full Text] [Related]  

  • 10. Oxybutynin-associated esotropia.
    Wong EY; Harding A; Kowal L
    J AAPOS; 2007 Dec; 11(6):624-5. PubMed ID: 18086433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxybutynin-induced reflux esophagitis.
    Lee M; Sharifi R
    DICP; 1990 Jun; 24(6):583-5. PubMed ID: 2360335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectrum of central anticholinergic adverse effects associated with oxybutynin: comparison of pediatric and adult cases.
    Gish P; Mosholder AD; Truffa M; Johann-Liang R
    J Pediatr; 2009 Sep; 155(3):432-4. PubMed ID: 19732583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Schaefer W
    Int J Urol; 2007 Jul; 14(7):670; author reply 670-1. PubMed ID: 17645621
    [No Abstract]   [Full Text] [Related]  

  • 14. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
    Ho C
    Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oxybutynin chloride in pediatrics: extenuating circumstances].
    Aubert D
    Arch Fr Pediatr; 1988 May; 45(5):375-6. PubMed ID: 3415420
    [No Abstract]   [Full Text] [Related]  

  • 18. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
    Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
    Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can oxybutynin cause peripheral neuropathy?
    Patel HR; Albehussi S; Arya M; Miller RA
    J Urol; 2002 Aug; 168(2):646. PubMed ID: 12131334
    [No Abstract]   [Full Text] [Related]  

  • 20. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.